• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Orion

67.20 EUR

-1.32 %

14,401 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.32 %
-2.18 %
-0.74 %
+5.58 %
+9.62 %
+12.47 %
+66.79 %
+91.95 %
+498.40 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
9.48B EUR
Turnover
9.21M EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
24.04.2026
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Views on Orion’s share price can validly be presented within a fairly wide range. This €60 is fine, Inderes’s (Inden) €80 is fine, and the €100 presented by Erkki Sinkko in the media is also fine. This isn’t a bargain-bin stock, but cash is flowing in massively, all the company’s...
4/24/2026, 6:58 AM
by PörssiPatruuna
20
Presenting results at ASCO does not guarantee brilliant results yet, but it does show that the findings are worthy of ASCO, which is a truly massive and significant event in oncology. Orion has already stated that ODM-212 showed clinical activity and tolerable safety in Phase 1, ...
5/21/2026, 9:24 AM
by Vino Pino
12
Here are Antti’s comments on the first results of Orion’s ODM-212 candidate Orion announced over the weekend preliminary results from the Phase I/II clinical trial of the cancer drug candidate ODM-212. Based on the results presented at the ASCO congress, the drug candidate has been...
yesterday
by Sijoittaja-alokas
10
The ASCO abstract for the First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES) has been published: First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES). - ASCO As with other similar early-...
5/22/2026, 7:55 AM
by Vino Pino
10
Inderes Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta... ORION OYJ LEHDISTÖTIEDOTE 30.5.2026 KLO 21.30 Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) potilailla, joilla on kiinteitä kasvaimia...
5/30/2026, 6:51 PM
by Dissidentti
9
Here’s a new company report from Siltanen after Q1. Orion’s Q1 was again strong and in line with our expectations. Revenue grew by 18% and operating profit by 47%, supported by Nubeqa’s high-margin growth. Among other business areas, Branded Products developed particularly well with...
4/24/2026, 6:11 AM
by Sijoittaja-alokas
9
Here is Liisa’s interview regarding Orion’s development. Inderes Orion Q1’26: Strategian mukaista kasvua - Inderes Aika: 23.04.2026 klo 15.30 Orionin voimakas kasvu jatkuu strategian mukaisesti Nubeqa kärjessä. Toimitusjohtaja Liisa Hurme kommentoi. 00:00 Orion’s development 00:50...
4/23/2026, 1:30 PM
by Verneri Pulkkinen
8
Read more on our forum
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7.
2026

Interim report Q2'26

19.10.
2026

Half year dividend

28.10.
2026

Interim report Q3'26

Regulatory press releaseyesterday

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Press release5/30/2026, 6:30 PM

Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

Orion
Press release5/21/2026, 7:30 AM

Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting

Orion

Join Inderes community

Research, tools and community to support better investment decisions.

FREE account
The market's most popular morning review
Analysts' recommendations and comments
Stock comparison and the investor discussion forum
PREMIUM account
All company reports and analyses
Premium content: model portfolio, insider transactions, Premium articles
Inderes MCP: Inderes data directly into your AI tools
Create account
Regulatory press release5/15/2026, 6:00 AM

105,950 Orion Corporation A shares converted into B shares

Orion
Press release5/12/2026, 7:30 AM

Orion Animal Health receives US FDA approval for Tessie® (tasipimidine oral solution) for the treatment of noise aversion and separation anxiety in dogs

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Ari Lehtoranta

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Sophie Papa

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Kari Jussi Aho

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Henrik Stenqvist

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Minna Maasilta

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Hilpi Rautelin

Orion
Regulatory press release5/4/2026, 1:00 PM

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

Orion
Regulatory press release4/27/2026, 9:00 AM

Composition of the Nomination Committee of Orion Corporation

Orion
Orion, Webcast, Q1'26
Webcast4/23/2026, 11:00 AM

Orion, Webcast, Q1'26

Orion
Regulatory press release4/23/2026, 9:00 AM

Orion Group Interim report January–March 2026

Orion
Press release4/23/2026, 6:00 AM

Orion Pharma initiates TEADCO Phase 1b/2 basket trial evaluating ODM-212 in combination with standard of care treatments in patients with select advanced solid tumours

Orion
Press release4/20/2026, 1:00 PM

Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA

Orion
Press release4/10/2026, 6:00 AM

Orion publishes Interim Report for January–March 2026 and holds a webcast on 23 April 2026

Orion
Regulatory press release4/1/2026, 1:00 PM

Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines

Orion